Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.

Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.

Zhitong FinanceApr 28 05:09 ET

Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus

Seeking AlphaApr 27 14:10 ET

The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.

A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.

Zhitong FinanceApr 25 23:38 ET

Vanda Claims FDA 'Unlawfully' Delays Hearing Request on Tradipitant Decision

Seeking AlphaApr 23 16:58 ET

9 Health Care Stocks With Whale Alerts In Today's Session

BenzingaApr 22 13:35 ET

Humanized Mouse and Rat Model Market Worth US$409.8 Million in 2030 With 8.2% CAGR | MarketsandMarkets

PR NewswireApr 22 10:30 ET